Tuberculosis, a disease affecting over 10 million individuals annually, faces a significant challenge – about 40% of cases remain undiagnosed. This critical gap in detection arises from the limitations of sputum-based testing, which many patients, especially those without symptoms, struggle to provide. Additionally, collecting sputum in low-resource settings poses a significant challenge. To address these issues, Tulane University has introduced a groundbreaking CRISPR-based test, ActCRISPR-TB, designed to detect Mycobacterium tuberculosis (Mtb) DNA from a simple tongue swab.
The ActCRISPR-TB test combines isothermal amplification and CRISPR-Cas12a detection in a single reaction, providing a rapid and efficient screening method. Within an hour, this test can identify TB infection through a paper strip readout, resembling the convenience of a home COVID-19 test kit. In a recent study published in Nature Communications, titled “Sensitive pathogen DNA detection by a multi-guide RNA Cas12a assay favoring trans- versus cis-cleavage,” the ActCRISPR-TB test demonstrated a 74% detection rate in tongue swab samples, surpassing the sensitivity of traditional testing methods, which achieved only a 56% success rate on similar specimens. Notably, the sensitivity was even higher for respiratory samples (93%), pediatric stool (83%), and adult spinal fluid (93%), highlighting its potential to diagnose TB in individuals unable to provide sputum samples.
Lead author Zhen Huang, PhD, emphasized the critical need for point-of-care TB diagnostics, especially in impoverished regions where the majority of TB cases are concentrated. The reliance on sputum testing, which is unfeasible for a significant percentage of symptomatic and asymptomatic patients, underscores the necessity for alternative screening approaches. By focusing on oral samples that are easier to collect, ActCRISPR-TB paves the way for large-scale screening initiatives in communities lacking extensive medical resources and laboratory facilities.
The technology behind ActCRISPR-TB builds upon the team’s prior work on a two-step CRISPR assay designed to detect Mycobacterium tuberculosis cell-free DNA in blood with high sensitivity and specificity. By consolidating this process into a single tube, the new test minimizes contamination risks and reduces the need for sophisticated equipment. Through validation on over 600 clinical specimens encompassing various sample types, including adult respiratory, pediatric stool, and adult cerebral spinal fluid specimens, the team has demonstrated the efficacy of the ActCRISPR-TB method.
The utilization of guide RNAs that promote trans-cleavage activity enhances the sensitivity of the test, with potential for further improvement by employing Cas12a RNPs targeting distinct sites on the target amplicon. The simplicity of the test procedure, which involves adding a tongue swab to a preloaded tube containing reagents and a lateral-flow test strip, enables rapid results within 45 minutes without the requirement for specialized equipment.
Addressing the challenges of complexity and contamination, Huang discussed the comparative analysis of their assay with other CRISPR-based methods for TB diagnostics, emphasizing the superior performance of ActCRISPR-TB. Looking ahead, the research team envisions expanding the platform to encompass a broader range of pathogens by integrating artificial intelligence (AI) into the system. Huang highlighted the potential for AI to enhance screening efficiency and facilitate the adaptation of the assay to emergent infectious diseases such as COVID-19 and monkeypox.
While the initial results of the ActCRISPR-TB test are promising, further community-based studies are essential to validate its performance in real-world screening scenarios, particularly among asymptomatic individuals with minimal bacterial loads. The authors acknowledged challenges associated with tongue swab testing, noting discrepancies in results compared to sputum testing, attributed to lower M. tuberculosis DNA levels on the tongue and variations influenced by sampling techniques, disease severity, and daily activities affecting respiratory material transfer to the oral cavity. Drawing parallels from COVID-19 testing strategies, such as repeated testing or utilizing more homogeneous saliva samples, may offer solutions to these challenges.
By eliminating the reliance on sputum samples and expensive equipment, ActCRISPR-TB presents a promising avenue for early TB detection and treatment, aligning with the global objective of eradicating tuberculosis. The innovative approach of leveraging CRISPR technology for oral-based TB screening signifies a transformative shift in tuberculosis diagnostics, offering hope for improved healthcare outcomes and disease control on a global scale.
Key Takeaways:
- The ActCRISPR-TB test revolutionizes tuberculosis screening by enabling detection from oral samples.
- This innovative CRISPR-based approach offers rapid results with high sensitivity, outperforming traditional testing methods.
- The integration of artificial intelligence (AI) holds the potential to expand the platform to target a broader range of pathogens.
- Challenges persist in translating tongue swab-based diagnostics into clinical practice, necessitating further validation studies and refinement of testing protocols.
Tags: biotech
Read more on genengnews.com